Azedra injection – first treatment approved for rare adrenal tumors

The U.S. Food and Drug Administration approved Azedra (iobenguane I 131) injection for intravenous use for the treatment of adults and adolescents age 12 and older with rare tumors of the adrenal gland (pheochromocytoma or paraganglioma) that cannot be surgically removed (unresectable), have spread beyond the original tumor site and require systemic anticancer therapy. This … Read more

Preventing disparities in colon cancer screening

How to prevent disparities in colon cancer screening – People living in poverty are less likely to be screened regularly for colorectal cancer — and more likely to develop the disease and die from it. How to end these disparities — and raise screening rates, lower disease rates, and prevent deaths?

Vedolizumab an effective treatment for Crohn’s disease and ulcerative colitis

Studies show vedolizumab is an effective treatment for Crohn’s disease and ulcerative colitis – Investigational antibody vedolizumab is an effective treatment for those suffering from ulcerative colitis (UC) and Crohn’s disease (CD) when other treatments have failed, revealed in an international clinical trial.

Darbepoetin alfa does not improve health of anemic heart failure patients

Cleveland Clinic research shows anemia drug does not improve health of anemic heart failure patients — Phase 3 findings published in NEJM provide answers about treatment with darbepoetin alfa – Researchers from Cleveland Clinic and Sweden-based Sahlgrenska University Hospital have found that a commonly used drug to treat anemia in heart failure patients – darbepoetin alfa – does not improve patients’ health, nor does it reduce their risk of death from heart failure.

Anemia drug Omontys recalled due to anaphylaxis

US FDA alerts health care providers of recall of anemia drug Omontys – In US, Omontys Injection is recalled due to reports of anaphylaxis, a serious and life-threatening allergic reaction. Omontys is used to treat anemia in adult dialysis patients. Until further notice, health care providers should stop using Omontys.

Early clamping may interrupt humankind’s first natural stem cell transplant

Do we clamp the umbilical cord too soon? — USF researchers: Early clamping may interrupt humankind’s first ‘natural stem cell transplant’ – The timing of umbilical cord clamping at birth should be delayed just a few minutes longer, suggest researchers at the University of South Florida’s Center of Excellence for Aging and Brain Repair.

Restless legs syndrome appears to occur within families

Restless Legs Syndrome Appears to Occur Within Families – Restless legs syndrome appears to aggregate in families, and the siblings of those who are severely affected appear to have an increased risk of developing the disease, according to a report in the May issue of Archives of Neurology, one of the JAMA/Archives journals.

New safety plan for agents used to treat chemotherapy related anemia

FDA Announces New Safety Plan for Agents Used to Treat Chemotherapy-Related Anemia – The U.S. Food and Drug Administration today approved a risk management program to inform healthcare providers and their patients about the risks of a class of drugs called Erythropoiesis-Stimulating Agents (ESAs).

Measuring and modeling blood flow in malaria

Measuring and modeling blood flow in malaria — Fluid Dynamics Conference in Minneapolis highlights – When people have malaria, they are infected with Plasmodium parasites, which enter the body from the saliva of a mosquito, infect cells in the liver, and then spread to red blood cells.

New iPS therapy pioneered for heart attacks

Induced pluripotent stem cells repair heart, Mayo Clinic study shows — New iPS therapy pioneered for heart attacks. – Induced pluripotent stem (iPS) cells can be used to treat heart disease, revealed by researchers at Mayo Clinic, USA. iPS cells are stem cells converted from adult cells.

Do NOT follow this link or you will be banned from the site!